Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma.
alcohol-related liver disease
cancer-diagnosis
cirrhosis
diagnostic tests
hepatocellular carcinoma
non-alcoholic fatty liver disease
viral hepatitis
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
19
09
2023
received:
08
06
2023
accepted:
23
09
2023
pubmed:
25
10
2023
medline:
25
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with one of the highest cancer-related mortality rates worldwide. Early diagnosis is crucial for improving the therapeutic options and reducing the disease-related mortality. To investigate serum N-glycomics as diagnostic markers for HCC. We performed a comprehensive search in PubMed, EMBASE, Web of Science and Scopus through August 17, 2023. Eligible studies assessed the potential use of serum N-glycomics as diagnostic biomarkers for HCC. Study selection, data extraction and quality assessment were performed by two independent reviewers. Of the 48 articles included, 11 evaluated the utility of N-glycomics for the diagnosis of HCC in whole serum while the remaining articles focused on specific protein glycoforms or protein levels. Of these specific proteins, haptoglobin, alpha-fetoprotein (AFP), kininogen (Kin), α-1-antitrypsin and Golgi protein 73 (GP73) were the most frequently studied. Increased levels of fucosylation and branching presented as the most prevalent post-translational modifications of glycoproteins in patients with HCC compared to controls. Notably, glycomics-based biomarkers may provide a clinical benefit for the diagnosis of early HCC, as several algorithms achieved AUCs between 0.92-0.97. However, these were based on single studies with limited sample sizes and should therefore be validated. Alterations in serum N-glycomics, characterised by increased levels of fucosylation and branching, have potential as diagnostic biomarkers for HCC. Optimisation of study design, patient selection and analysing techniques are needed before clinical implementation will be possible.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with one of the highest cancer-related mortality rates worldwide. Early diagnosis is crucial for improving the therapeutic options and reducing the disease-related mortality.
AIM
OBJECTIVE
To investigate serum N-glycomics as diagnostic markers for HCC.
METHODS
METHODS
We performed a comprehensive search in PubMed, EMBASE, Web of Science and Scopus through August 17, 2023. Eligible studies assessed the potential use of serum N-glycomics as diagnostic biomarkers for HCC. Study selection, data extraction and quality assessment were performed by two independent reviewers.
RESULTS
RESULTS
Of the 48 articles included, 11 evaluated the utility of N-glycomics for the diagnosis of HCC in whole serum while the remaining articles focused on specific protein glycoforms or protein levels. Of these specific proteins, haptoglobin, alpha-fetoprotein (AFP), kininogen (Kin), α-1-antitrypsin and Golgi protein 73 (GP73) were the most frequently studied. Increased levels of fucosylation and branching presented as the most prevalent post-translational modifications of glycoproteins in patients with HCC compared to controls. Notably, glycomics-based biomarkers may provide a clinical benefit for the diagnosis of early HCC, as several algorithms achieved AUCs between 0.92-0.97. However, these were based on single studies with limited sample sizes and should therefore be validated.
CONCLUSIONS
CONCLUSIONS
Alterations in serum N-glycomics, characterised by increased levels of fucosylation and branching, have potential as diagnostic biomarkers for HCC. Optimisation of study design, patient selection and analysing techniques are needed before clinical implementation will be possible.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-38Subventions
Organisme : Ghent University Hospital (FIKO)
Organisme : Research Foundation - Flanders
Organisme : Stichting tegen Kanker
Organisme : Kom op tegen Kanker
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249. https://doi.org/10.3322/caac.21660
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706-1718.e1. https://doi.org/10.1053/j.gastro.2018.01.064
Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, et al. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021;4:CD013346. https://doi.org/10.1002/14651858.CD013346.pub2
Tayob N, Lok ASF, Feng Z. A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. Stat Med. 2022;41:2338-2353. https://doi.org/10.1002/sim.9358
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540-555. https://doi.org/10.1038/nrc3982
Verhelst X, Dias AM, Colombel JF, Vermeire S, van Vlierberghe H, Callewaert N, et al. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. Gastroenterology. 2020;158:95-110. https://doi.org/10.1053/j.gastro.2019.08.060
Vanderschaeghe D, Laroy W, Sablon E, Halfon P, van Hecke A, Delanghe J, et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics. 2009;8:986-994. https://doi.org/10.1074/mcp.M800470-MCP200
Callewaert N, Vlierberghe HV, Hecke AV, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10:429-434. https://doi.org/10.1038/nm1006
Blomme B, Francque S, Trépo E, Libbrecht L, Vanderschaeghe D, Verrijken A, et al. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis. 2012;44:315-322. https://doi.org/10.1016/j.dld.2011.10.015
Verhelst X, Vanderschaeghe D, Castéra L, Raes T, Geerts A, Francoz C, et al. A Glycomics-based test predicts the development of hepatocellular carcinoma in cirrhosis. Clin Cancer Res. 2017;23:2750-2758. https://doi.org/10.1158/1078-0432.Ccr-16-1500
Verhelst X, Geerts A, Callewaert N, Van Vlierberghe H. The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation. Acta Gastroenterol Belg. 2019;82:309-313.
de Haan N, Wuhrer M, Ruhaak LR. Mass spectrometry in clinical glycomics: the path from biomarker identification to clinical implementation. Clin Mass Spectrom. 2020;18:1-12. https://doi.org/10.1016/j.clinms.2020.08.001
Verhelst X, Geerts A, Jochmans I, Vanderschaeghe D, Paradissis A, Vanlander A, et al. Glycome patterns of Perfusate in livers before transplantation associate with primary nonfunction. Gastroenterology. 2018;154:1361-1368. https://doi.org/10.1053/j.gastro.2017.12.027
Vanderschaeghe D, Meuris L, Raes T, Grootaert H, van Hecke A, Verhelst X, et al. Endoglycosidase S enables a highly simplified clinical chemistry procedure for direct assessment of serum IgG undergalactosylation in chronic inflammatory disease. Mol Cell Proteomics. 2018;17:2508-2517. https://doi.org/10.1074/mcp.TIR118.000740
Verhelst X, Geerts A, Colman R, Vanlander A, Degroote H, Abreu de Carvalho L, et al. Serum Glycomics on postoperative day 7 are associated with graft loss within 3 months after liver transplantation regardless of early allograft dysfunction. Transplantation. 2021;105:2404-2410. https://doi.org/10.1097/tp.0000000000003567
Somers N, Vandekerckhove E, Geerts A, Degroote H, Lefere S, Devisscher L, et al. Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. Acta Clin Belg. 2023;78:96-102. https://doi.org/10.1080/17843286.2022.2072110
Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. J Hepatol. 2009;50:592-603. https://doi.org/10.1016/j.jhep.2008.12.010
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89. https://doi.org/10.1186/s13643-021-01626-4
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
Comunale MA, Wang M, Anbarasan N, Betesh L, Karabudak A, Moritz E, et al. Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma. Proteomics Clin Appl. 2013;7:690-700. https://doi.org/10.1002/prca.201200125
Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007;46:1426-1435. https://doi.org/10.1002/hep.21855
Guo L, Wan L, Hu Y, Huang H, He B, Wen Z. Serum N-glycan profiling as a diagnostic biomarker for the identification of hepatitis B virus-associated hepatocellular carcinoma. J Gastrointest Oncol. 2022;13:344-354. https://doi.org/10.21037/jgo-22-93
Wan L, Guo L, Hu Y, Huang H, Zhang M, Xu K, et al. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer. Clin Biochem. 2021;89:44-50. https://doi.org/10.1016/j.clinbiochem.2020.12.005
Fang M, Zhao YP, Zhou FG, Lu LG, Qi P, Wang H, et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010;127:148-159. https://doi.org/10.1002/ijc.25030
Higashi M, Yoshimura T, Usui N, Kano Y, Deguchi A, Tanabe K, et al. A potential serum N-glycan biomarker for hepatitis C virus-related early-stage hepatocellular carcinoma with liver cirrhosis. Int J Mol Sci. 2020;21:8913. https://doi.org/10.3390/ijms21238913
Huang C, Fang M, Feng H, Liu L, Li Y, Xu X, et al. N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: a large-scale multicenter study. Int J Cancer. 2021;149:717-727. https://doi.org/10.1002/ijc.33564
Miyahara K, Nouso K, Dohi C, Morimoto Y, Kinugasa H, Wada N, et al. Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma. Hepatol Res. 2015;45:986-993. https://doi.org/10.1111/hepr.12441
Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, et al. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res. 2009;15:1808-1813. https://doi.org/10.1158/1078-0432.Ccr-07-5261
Liu Y, He J, Li C, Benitez R, Fu S, Marrero J, et al. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res. 2010;9:798-805. https://doi.org/10.1021/pr900715p
Tan Y, Zhu J, Gutierrez Reyes CD, Lin Y, Tan Z, Wu Z, et al. Discovery of core-fucosylated glycopeptides as diagnostic biomarkers for early HCC in patients with NASH cirrhosis using LC-HCD-PRM-MS/MS. ACS Omega. 2023;8:12467-12480. https://doi.org/10.1021/acsomega.3c00519
Zhang S, Shu H, Luo K, Kang X, Zhang Y, Lu H, et al. N-linked glycan changes of serum haptoglobin β chain in liver disease patients. Mol Biosyst. 2011;7:1621-1628. https://doi.org/10.1039/c1mb05020f
Shalably NM, Badawi R, Hawash N, Abd-Elsalam S, Elkhalawany W, Hameed AAEI, et al. Evaluation of fucosylated haptoglobin as a diagnostic biomarker for hepatocellular carcinoma in Egypt. Open Biomark J. 2019;9:31-37. https://doi.org/10.2174/1875318301909010031
Asazawa H, Kamada Y, Takeda Y, Takamatsu S, Shinzaki S, Kim Y, et al. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med. 2015;53:95-102. https://doi.org/10.1515/cclm-2014-0427
Shu H, Zhang S, Kang X, Li S, Qin X, Sun C, et al. Protein expression and fucosylated glycans of the serum haptoglobin-{beta} subunit in hepatitis B virus-based liver diseases. Acta Biochim Biophys Sin (Shanghai). 2011;43:528-534. https://doi.org/10.1093/abbs/gmr038
Shang S, Li W, Qin X, Zhang S, Liu Y. Aided diagnosis of hepatocellular carcinoma using serum fucosylated haptoglobin ratios. J Cancer. 2017;8:887-893. https://doi.org/10.7150/jca.17747
Dalal K, Dalal B, Bhatia S, Shukla A, Shankarkumar A. Analysis of serum haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in hepatitis B virus infection. Clin Chim Acta. 2019;495:309-317. https://doi.org/10.1016/j.cca.2019.04.072
Zhu J, Lin Z, Wu J, Yin H, Dai J, Feng Z, et al. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res. 2014;13:2986-2997. https://doi.org/10.1021/pr500128t
Zhu J, Wu J, Yin H, Marrero J, Lubman DM. Mass spectrometric N-glycan analysis of haptoglobin from patient serum samples using a 96-well plate format. J Proteome Res. 2015;14:4932-4939. https://doi.org/10.1021/acs.jproteome.5b00662
Peta V, Zhu J, Lubman DM, Huguet S, Imbert-Bismutd F, Bolbach G, et al. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Clin Res Hepatol Gastroenterol. 2020;44:681-691. https://doi.org/10.1016/j.clinre.2019.12.010
Mondal G, Saroha A, Bose PP, Chatterjee BP. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J. 2016;33:209-218. https://doi.org/10.1007/s10719-016-9658-2
Lin Y, Zhu J, Zhang J, Dai J, Liu S, Arroyo A, et al. Glycopeptides with Sialyl Lewis antigen in serum haptoglobin as candidate biomarkers for nonalcoholic steatohepatitis hepatocellular carcinoma using a higher-energy collision-induced dissociation parallel reaction monitoring-mass spectrometry method. ACS Omega. 2022;7:22850-22860. https://doi.org/10.1021/acsomega.2c02600
Ang IL, Poon TCW, Lai PBS, Chan ATC, Ngai SM, Hui AY, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res. 2006;5:2691-2700. https://doi.org/10.1021/pr060109r
Lee HJ, Cha HJ, Lim JS, Lee SH, Song SY, Kim H, et al. Abundance-ratio-based semiquantitative analysis of site-specific N-linked glycopeptides present in the plasma of hepatocellular carcinoma patients. J Proteome Res. 2014;13:2328-2338. https://doi.org/10.1021/pr4011519
Lin Y, Zhu J, Pan L, Zhang J, Tan Z, Olivares J, et al. A panel of glycopeptides as candidate biomarkers for early diagnosis of NASH hepatocellular carcinoma using a stepped HCD method and PRM evaluation. J Proteome Res. 2021;20:3278-3289. https://doi.org/10.1021/acs.jproteome.1c00175
Kim H, Kim K, Jin J, Park J, Yu SJ, Yoon JH, et al. Measurement of glycosylated alpha-fetoprotein improves diagnostic power over the native form in hepatocellular carcinoma. PloS One. 2014;9:e110366. https://doi.org/10.1371/journal.pone.0110366
Kim KH, Lee SY, Hwang H, Lee JY, Ji ES, An HJ, et al. Direct monitoring of fucosylated glycopeptides of alpha-fetoprotein in human serum for early hepatocellular carcinoma by liquid chromatography-tandem mass spectrometry with immunoprecipitation. Proteomics Clin Appl. 2018;12:e1800062. https://doi.org/10.1002/prca.201800062
Wu M, Liu Z, Zhang A, Li N. Associated measurement of fucosylated levels of AFP, DCP, and GPC3 for early diagnosis in hepatocellular carcinoma. Int J Biol Markers. 2019;34:20-26. https://doi.org/10.1177/1724600818812472
Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1914-1921. https://doi.org/10.1158/1055-9965.Epi-08-0980
Wang M, Comunale MA, Herrera H, Betesh L, Kono Y, Mehta A. Identification of IgM as a contaminant in lectin-FLISA assays for HCC detection. Biochem Biophys Res Commun. 2016;476:140-145. https://doi.org/10.1016/j.bbrc.2016.05.027
Wang M, Sanda M, Comunale MA, Herrera H, Swindell C, Kono Y, et al. Changes in the glycosylation of kininogen and the development of a kininogen-based algorithm for the early detection of HCC. Cancer Epidemiol Biomarkers Prev. 2017;26:795-803. https://doi.org/10.1158/1055-9965.Epi-16-0974
Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P, di Bisceglie AM, et al. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One. 2010;5:e12419. https://doi.org/10.1371/journal.pone.0012419
Jiang K, Shang S, Li W, Guo K, Qin X, Zhang S, et al. Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases. Glycoconj J. 2015;32:657-664. https://doi.org/10.1007/s10719-015-9614-6
Zhao Y, Zhang L, Huo L, Pei L, Li Q, Li H, et al. Clinical significance of fucosylated GP73 in the differential diagnosis of hepatocellular carcinoma. Int J Biol Markers. 2018;33:439-446. https://doi.org/10.1177/1724600818796646
Yi CH, Weng HL, Zhou FG, Fang M, Ji J, Cheng C, et al. Elevated core-fucosylated IgG is a new marker for hepatitis B virus-related hepatocellular carcinoma. Onco Targets Ther. 2015;4:e1011503. https://doi.org/10.1080/2162402x.2015.1011503
Wang M, Singal AG, Parikh N, Kono Y, Marrero J, Mehta A. A biomarker panel based upon AFP, fucosylated kininogen and PEG-precipitated IgG is highly accurate for the early detection hepatocellular carcinoma in patients with cirrhosis in phase II and phase III biomarker evaluation. Cancers (Basel). 2022;14:5970. https://doi.org/10.3390/cancers14235970
Sun C, Chen P, Chen Q, Sun L, Kang X, Qin X, et al. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta Biochim Biophys Sin (Shanghai). 2012;44:765-773. https://doi.org/10.1093/abbs/gms055
Zhang S, Jiang K, Zhang Q, Guo K, Liu Y. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index. Glycoconj J. 2015;32:119-125. https://doi.org/10.1007/s10719-015-9576-8
Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2018;48:872-881. https://doi.org/10.1111/hepr.13187
Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, et al. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2011;20:1222-1229. https://doi.org/10.1158/1055-9965.Epi-10-1047
Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B, et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res. 2009;8:595-602. https://doi.org/10.1021/pr800752c
Debruyne EN, Vanderschaeghe D, van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem. 2010;56:823-831. https://doi.org/10.1373/clinchem.2009.139295
Li L, Gu X, Fang M, Ji J, Yi C, Gao C. The diagnostic value of serum fucosylated fetuin A in hepatitis B virus-related liver diseases. Clin Chem Lab Med. 2016;54:693-701. https://doi.org/10.1515/cclm-2015-0307
Liang J, Zhu J, Wang M, Singal AG, Odewole M, Kagan S, et al. Evaluation of AGP fucosylation as a marker for hepatocellular carcinoma of three different etiologies. Sci Rep. 2019;9:11580. https://doi.org/10.1038/s41598-019-48043-1
Tanabe K, Kitagawa K, Kojima N, Iijima S. Multifucosylated alpha-1-acid glycoprotein as a novel marker for hepatocellular carcinoma. J Proteome Res. 2016;15:2935-2944. https://doi.org/10.1021/acs.jproteome.5b01145
Lin Y, Zhang J, Arroyo A, Singal AG, Parikh ND, Lubman DM. A fucosylated glycopeptide as a candidate biomarker for early diagnosis of NASH hepatocellular carcinoma using a stepped HCD method and PRM evaluation. Front Oncol. 2022;12:818001. https://doi.org/10.3389/fonc.2022.818001
Yin H, Lin Z, Nie S, Wu J, Tan Z, Zhu J, et al. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res. 2014;13:2887-2896. https://doi.org/10.1021/pr500043k
Yin H, Tan Z, Wu J, Zhu J, Shedden KA, Marrero J, et al. Mass-selected site-specific Core-Fucosylation of serum proteins in hepatocellular carcinoma. J Proteome Res. 2015;14:4876-4884. https://doi.org/10.1021/acs.jproteome.5b00718
Nagel T, Klaus F, Ibanez IG, Wege H, Lohse A, Meyer B. Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver cancer and liver cirrhosis. Anal Bioanal Chem. 2018;410:7965-7977. https://doi.org/10.1007/s00216-018-1418-7
Guan MC, Zhang SY, Ding Q, Li N, Fu TT, Zhang GX, et al. The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis. J Clin Med. 2023;12:949. https://doi.org/10.3390/jcm12030949
Best J, Bilgi H, Heider D, Schotten C, Manka P, Bedreli S, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54:1296-1305. https://doi.org/10.1055/s-0042-119529
Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L. Multiple “Omics” data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol. 2019;25:4199-4212. https://doi.org/10.3748/wjg.v25.i30.4199
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110-118. https://doi.org/10.1053/j.gastro.2009.04.005
Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019;69:1983-1994. https://doi.org/10.1002/hep.30233
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23:144-153. https://doi.org/10.1158/1055-9965.Epi-13-0870
Tang JC, Feng YL, Guo T, Xie AY, Cai XJ. Circulating tumor DNA in hepatocellular carcinoma: trends and challenges. Cell Biosci. 2016;6:32. https://doi.org/10.1186/s13578-016-0100-z
Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol. 2011;91:702-707. https://doi.org/10.1016/j.yexmp.2011.08.004
Kang P, Madera M, Alley WR Jr, Goldman R, Mechref Y, Novotny MV. Glycomic alterations in the highly-abundant and lesser-abundant blood serum protein fractions for patients diagnosed with hepatocellular carcinoma. Int J Mass Spectrom. 2011;305:185-198. https://doi.org/10.1016/j.ijms.2010.11.007
Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H. Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol. 1998;13:610-619. https://doi.org/10.1111/j.1440-1746.1998.tb00699.x
Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, et al. Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol. 1998;124:27-30. https://doi.org/10.1007/s004320050129
Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem. 2008;143:725-729. https://doi.org/10.1093/jb/mvn011
Norton PA, Mehta AS. Expression of genes that control core fucosylation in hepatocellular carcinoma: systematic review. World J Gastroenterol. 2019;25:2947-2960. https://doi.org/10.3748/wjg.v25.i23.2947
Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem. 2006;281:29797-29806. https://doi.org/10.1074/jbc.M605697200
Singal AG, Tayob N, Mehta A, Marrero JA, Jin Q, Lau J, et al. Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis. Clin Gastroenterol Hepatol. 2022;20:953-955.e2. https://doi.org/10.1016/j.cgh.2021.04.018